Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian ...

Lupin announced that it has entered into a license and supply agreement with Zentiva, k.s. for the commercialization of its biosimilar Certolizumab Pegol.

The Global Biosimilars Market size is projected to be valued at USD 27.20 billion in 2023 and reach USD 76.20 billion by 2030 ...

The $440 million investment in a new production plant in Brnik brings total planned investment in Slovenia to more than $1.1 ...

Lupin & Zentiva ink licensing and supply agreement for commercializing biosimilar Certolizumab Pegol: Our Bureau, Mumbai Wednesday, July 9, 2025, 16:20 Hrs [IST] Global Pharma maj ...

The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Apotex Inc. ("Apotex" or the "Company"), the Canadian-based global health company, today announced that Health Canada has ...

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment ...

Biocon Biologics Receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars Bengaluru, Karnataka, India, July 7, 2025  Biocon Biologics Ltd (BBL), a fully integrated global biosimilars ...

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA®</ ...